DKK4 appears to play a similar role to DKK1 to antagonize the Wnt/β-catenin pathway, and relative to all other DKK family members, genetic variants in DKK4 are more common in prostate cancer (Table 1 and Tables S1–S4) [64,65,66]. This evidence concerns the gene DKK4 and prostate carcinoma.